Bertram Glaß

9.8k total citations · 4 hit papers
102 papers, 4.1k citations indexed

About

Bertram Glaß is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Bertram Glaß has authored 102 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 44 papers in Pathology and Forensic Medicine and 33 papers in Hematology. Recurrent topics in Bertram Glaß's work include Lymphoma Diagnosis and Treatment (44 papers), CAR-T cell therapy research (37 papers) and Hematopoietic Stem Cell Transplantation (26 papers). Bertram Glaß is often cited by papers focused on Lymphoma Diagnosis and Treatment (44 papers), CAR-T cell therapy research (37 papers) and Hematopoietic Stem Cell Transplantation (26 papers). Bertram Glaß collaborates with scholars based in Germany, France and United States. Bertram Glaß's co-authors include Norbert Schmitz, Michael Pfreundschuh, Marita Ziepert, Markus Loeffler, Christian Gisselbrecht, Craig H. Moskowitz, Ofer Shpilberg, Nicolas Mounier, Marek Trněný and Nicolas Ketterer and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Bertram Glaß

97 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

2010 1.1k citations Christian Gisselbrecht, Bertram Glaß et al. Journal of Clinical Oncology profile →
Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

2021 223 citations Jakob Passweg, Helen Baldomero et al. Bone Marrow Transplantation profile →
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

2022 186 citations Jeremy S. Abramson, Scott R. Solomon et al. Blood profile →
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

2022 159 citations John A. Snowden, Isabel Sánchez‐Ortega et al. Bone Marrow Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bertram Glaß Germany	26	2.4k	2.2k	1000	944	922	102	4.1k
Réda Bouabdallah France	28	1.9k 0.8×	2.0k 0.9×	913 0.9×	600 0.6×	1.5k 1.6×	101	4.0k
Nicolas Ketterer Switzerland	23	2.8k 1.2×	2.5k 1.2×	1.4k 1.4×	658 0.7×	1.1k 1.1×	69	4.5k
Lode J. Swinnen United States	32	1.5k 0.6×	2.4k 1.1×	664 0.7×	448 0.5×	931 1.0×	110	4.3k
J L Harousseau France	22	1.8k 0.7×	1.8k 0.8×	815 0.8×	590 0.6×	1.1k 1.2×	36	3.3k
Gustaaf W. van Imhoff Netherlands	31	2.3k 0.9×	1.9k 0.8×	979 1.0×	732 0.8×	308 0.3×	84	3.6k
Marcel Reiser Germany	28	2.5k 1.0×	1.9k 0.9×	1.3k 1.3×	714 0.8×	355 0.4×	124	3.6k
Luis F. Porrata United States	43	2.4k 1.0×	2.6k 1.2×	1.4k 1.4×	614 0.7×	1.7k 1.8×	211	5.4k
Marine Diviné France	39	2.8k 1.2×	2.2k 1.0×	1.3k 1.3×	830 0.9×	1.8k 1.9×	112	5.1k
Mark Hertzberg Australia	28	1.5k 0.6×	1.7k 0.8×	894 0.9×	273 0.3×	1.1k 1.2×	166	3.5k
Craig S. Sauter United States	29	1.2k 0.5×	3.4k 1.6×	598 0.6×	573 0.6×	732 0.8×	189	4.7k

Countries citing papers authored by Bertram Glaß

Since Specialization

Citations

This map shows the geographic impact of Bertram Glaß's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertram Glaß with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertram Glaß more than expected).

Fields of papers citing papers by Bertram Glaß

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bertram Glaß. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertram Glaß. The network helps show where Bertram Glaß may publish in the future.

Co-authorship network of co-authors of Bertram Glaß

This figure shows the co-authorship network connecting the top 25 collaborators of Bertram Glaß. A scholar is included among the top collaborators of Bertram Glaß based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bertram Glaß. Bertram Glaß is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Passweg, Jakob, Helen Baldomero, Fabio Ciceri, et al.. (2024). Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplantation. 59(6). 803–812. 27 indexed citations

Renders, Simon, Hervé Finel, William Townsend, et al.. (2024). Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study. Blood Advances. 8(21). 5571–5578.

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2024). Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncology. 20(21). 1455–1465. 1 indexed citations

Yakoub‐Agha, Ibrahim, Raffaella Greco, Francesco Onida, et al.. (2023). Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transplantation. 58(6). 696–700. 10 indexed citations

Westin, Jason R., Caron A. Jacobson, Julio C. Chávez, et al.. (2023). PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA. HemaSphere. 7(S3). e3278692–e3278692. 1 indexed citations

Passweg, Jakob, Helen Baldomero, Fabio Ciceri, et al.. (2023). Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation. 58(6). 647–658. 35 indexed citations

Schubert, Maria‐Luisa, Wolfgang Bethge, Francis Ayuk, et al.. (2023). Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study. Blood Advances. 7(20). 6191–6195. 9 indexed citations

Passweg, Jakob, Helen Baldomero, Christian Chabannon, et al.. (2022). Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation. 57(5). 742–752. 41 indexed citations

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Transplantation and Cellular Therapy. 28(3). S188–S189.

10.

Snowden, John A., Isabel Sánchez‐Ortega, Selim Corbacioglu, et al.. (2022). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplantation. 57(8). 1217–1239. 159 indexed citations breakdown →

11.

Passweg, Jakob, Helen Baldomero, Christian Chabannon, et al.. (2021). Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation. 56(7). 1651–1664. 223 indexed citations breakdown →

12.

Penack, Olaf, Christophe Peczynski, Mohamad Mohty, et al.. (2021). Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. Bone Marrow Transplantation. 57(2). 183–190. 17 indexed citations

13.

Brissot, Éolia, Myriam Labopin, Domenico Russo, et al.. (2020). Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation. 55(9). 1763–1772. 15 indexed citations

14.

Schmitz, Norbert, Maike Nickelsen, Bettina Altmann, et al.. (2015). Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial.. Journal of Clinical Oncology. 18 indexed citations

15.

Savage, Kerry J., Samira Zeynalova, Roopesh Kansara, et al.. (2014). Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma. Blood. 124(21). 394–394. 19 indexed citations

16.

Gisselbrecht, Christian, Bertram Glaß, Nicolas Mounier, et al.. (2010). Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology. 28(27). 4184–4190. 1117 indexed citations breakdown →

17.

Hasenkamp, Justin, et al.. (2009). Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Annals of Hematology. 89(3). 283–289. 10 indexed citations

18.

Rüchel, R., et al.. (2006). Un caso clínico de aspergilosis pulmonar que no respondió al tratamiento con caspofungina. Revista Iberoamericana de Micología. 23(2). 94–96. 5 indexed citations

19.

Glaß, Bertram, Marita Kloess, Marcel Reiser, et al.. (2005). Dose Escalated CHOP + Etoposide Followed by Repetitive Autologous Stem Cell Transplantation (MegaCHOEP) with or without Rituximab for Primary Treatment of Aggressive NHL.. Blood. 106(11). 1492–1492. 7 indexed citations

20.

Dreger, Peter, Nils von Neuhoff, Daniel M. Kruss, et al.. (2000). A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. Experimental Hematology. 28(10). 1187–1196. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact